Researchers at a meeting

Advisory Panel

Preclinical and Clinical Planning

Panel members with expertise in selecting and developing assays, animal models, structural models and clinical trials are assets to the successful and efficient discovery and development of therapeutics for clinical advancement.

Perry Molinoff, MD, Chair

Perry Molinoff, MD, Chair

Has more than 30 years’ experience in both the academic and industrial sectors

Chair, Innovation Support Center, Harrington Discovery Institute
Member, Scientific Advisory Board, BioMotiv
Professor, Pharmacology, University of Pennsylvania

Lawrence Olanoff, MD, PhD

Lawrence Olanoff, MD, PhD

An expert in preclinical and clinical planning and strategy with more than 30 years’ combined experience in clinical pharmacology and pharmaceutical development.

Special Advisor to the President for Corporate Relations, MUSC
Former President and COO, Forest Laboratories, Inc.

Patricia C. Weber, PhD

Patricia Weber, PhD

An industry and start-up consultant with broad experience in the utilization of structure-based drug design and biophysical approaches for the discovery of both small molecule drugs and protein biologics.

Former Senior Director, Structural Chemistry, Schering-Plough Research Institute

Medicinal Chemistry

Medicinal chemistry experts with decades of experience in the synthesis and alteration of organic compounds contribute to the discovery and optimization of lead compounds and series without claiming rights to any intellectual property. These industry veterans know how to help our scholars identify compounds with a high likelihood of becoming therapeutic agents.

Peter R Bernstein, PhDl

Peter Bernstein, PhD

A consultant in medicinal chemistry with more than 30 years’ experience in drug development and discovery at ICI Pharmaceuticals through its spin-off as Seneca Pharmaceuticals and subsequent merger with Astra Pharmaceuticals to form AstraZeneca Pharmaceuticals.

Former Senior Principal Scientist, CNS Chemistry, AstraZeneca Pharmaceuticals

William Greenlee, PhD

William Greenlee, PhD

A consultant in medicinal chemistry with more than 25 years’ experience in drug discovery and development.

Former VP, Schering-Plough
Former Senior Director, Merck

John J. Piwinski, PhD

John Piwinski, PhD

Has extensive expertise in small molecule drug discovery with over 30 years of experience in medicinal chemistry.

Former Senior Scientist, Revlon Health Care
Former VP, Schering-Plough

George Trainor, PhD

George Trainor, PhD

A consultant with 30 years’ experience in the biotechnology and pharmaceutical industries. Has expertise in drug discovery strategy development and execution, medicinal chemistry and the application of transformative technologies.

Former VP, Oncology and Early Discovery Chemistry, Bristol Myers Squibb

Pharmacology

Panel members with a strong background in pharmacology advise scholars on safety, toxicology, pharmacokinetics and pharmacodynamics, providing an expert eye to evaluate experimental results and suggest strategic next steps.

Martin A. Graham, PhD

Martin Graham, PhD

A consultant in pharmacology with more than 25 years’ research and development experience in small molecule and protein therapeutics from IND to NDA/BLA.

Former Director of Pharmacokinetics, Centocor - Johnson and Johnson
Former VP, Development, TetraLogic Pharmaceuticals

Charles Lindamood III, PhD, DABT

Charles Lindamood III, PhD, DABT

A toxicology and drug development expert with more than 30 years’ experience in pharmaceutical and biopharmaceutical toxicology and drug development.

Former Executive Director, Forest Laboratories
Former Study Director, Southern Research Institute

Regulatory Strategy and Planning

With an eye to the clinic, panel members with years of experience in regulatory strategy and planning offer an important perspective in guiding early discoveries toward investigational and marketing success.

Thomas Hohman, PhD

Thomas Hohman, PhD

A specialist in retinal research and development with extensive experience in the identification and assessment of licensing opportunities across multiple therapeutic areas.

Former VP, Retina Translation Medicine, Allergan and Alcon
Former Ophthalmology & Clinical Head, Novartis

Paul Williamson, M.D.

Paul Williamson, MD

A regulatory strategy expert with over 30 years of clinical and industry experience.

Former Senior Director, The Stem Cell Organization, formerly of Johnson & Johnson

Formulation

Formulation experts consider important aspects of a candidate drug including molecular size, activity, stability, and dosage considerations to ensure effective clinical advancement and therapeutic benefit.

John S. Kent, PhD

John Kent, PhD

A consultant in formulation with over 35 years of experience in pharmaceutical development.

VP, Theravance
Former VP, Pharmaceutical Sciences - Services, Allergan

Robert Lipper, PhD

Robert Lipper, PhD

President, Back Cove Pharma, LLC, providing consulting and education services in pharmaceutical development.

Former VP, Biopharmaceutics Research & Development, Bristol-Myers Squibb